# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
9, Journal, 0, 13, "Diabetes Care", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasJournal> \"Diabetes Care\"."
0, PublicationYear, 16, 20, "2004", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasPublicationYear> \"2004\"."
119, Duration, 51, 73, "Twelve - and 52 - week", "", 
212, Title, 51, 185, "Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes .", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasTitle> \"Twelve - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin - treated patients with type 2 diabetes .\"."
38502, Vildagliptin, 124, 130, "LAF237", "", 
8, Precondition, 134, 183, "metformin - treated patients with type 2 diabetes", "", "<http://ctro/data#Population_30694> <http://ctro/data#hasPrecondition> \"metformin - treated patients with type 2 diabetes\"."
12, Metformin, 134, 143, "metformin", "", 
13, Type2Diabetes, 168, 183, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
1, Author, 186, 195, "Ahr Ã© n B", "", 
2, Author, 204, 211, "Gomis R", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasAuthor> \"Gomis R\"."
3, Author, 214, 222, "Standl E", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasAuthor> \"Standl E\"."
4, Author, 225, 232, "Mills D", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasAuthor> \"Mills D\"."
5, Author, 235, 246, "Schweizer A", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasAuthor> \"Schweizer A\"."
7, Sweden, 346, 352, "Sweden", "", "<http://ctro/data#Population_30694> <http://ctro/data#hasCountry> <http://ctro/data#Sweden>."
213, ObjectiveDescription, 394, 564, "To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment .", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#hasObjectiveDescription> \"To assess the 12 - and 52 - week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment .\"."
120, Duration, 408, 426, "12 - and 52 - week", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#hasCTduration> \"12 - and 52 - week\"."
38402, Duration, 417, 426, "52 - week", "", 
38503, Vildagliptin, 477, 483, "LAF237", "", 
71, Placebo, 491, 498, "placebo", "", 
72, Type2Diabetes, 516, 531, "type 2 diabetes", "", 
73, Metformin, 543, 552, "metformin", "", 
19, Duration, 610, 619, "12 - week", "", 
20, Randomized, 622, 632, "randomized", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
21, DoubleBlind, 635, 649, "double - blind", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
22, Placebo, 652, 659, "placebo", "", 
23, NumberPatientsCT, 682, 685, "107", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#hasNumberPatientsCT> \"107\"."
24, Type2Diabetes, 700, 715, "type 2 diabetes", "", 
216, Duration, 723, 732, "40 - week", "", 
66, Duration, 849, 855, "1 year", "", 
25, Placebo, 858, 865, "Placebo", "", "<http://ctro/data#Medication_30759> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
88, NumberPatientsArm, 872, 874, "51", "", "<http://ctro/data#Arm_30731> <http://ctro/data#hasNumberPatientsArm> \"51\"."
38501, Vildagliptin, 880, 886, "LAF237", "", "<http://ctro/data#Medication_30752> <http://ctro/data#hasDrug> <http://ctro/data#Vildagliptin>."
28, DoseValue, 889, 891, "50", "", "<http://ctro/data#Medication_30752> <http://ctro/data#hasDoseValue> \"50\"."
29, mg, 892, 894, "mg", "", "<http://ctro/data#Medication_30752> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
30, Frequency, 895, 905, "once daily", "", "<http://ctro/data#Intervention_30740> <http://ctro/data#hasFrequency> \"once daily\"."
89, NumberPatientsArm, 912, 914, "56", "", "<http://ctro/data#Arm_30722> <http://ctro/data#hasNumberPatientsArm> \"56\"."
31, Metformin, 938, 947, "metformin", "", 
32, DoseValue, 960, 977, "1 , 500 - 3 , 000", "", 
33, mg, 978, 980, "mg", "", 
38403, Interval, 983, 986, "day", "", 
35, HbA1c, 991, 996, "HbA1c", "", 
142, FastingPlasmaGlucose, 1001, 1023, "fasting plasma glucose", "", 
143, FastingPlasmaGlucose, 1026, 1029, "FPG", "", 
144, TimePoint, 1107, 1115, "baseline", "", 
67, TimePoint, 1118, 1125, "week 12", "", 
68, TimePoint, 1132, 1139, "week 52", "", 
147, Randomized, 1164, 1174, "randomized", "", 
38506, Vildagliptin, 1178, 1184, "LAF237", "", 
38, HbA1c, 1196, 1201, "HbA1c", "", 
39, BaseLineValue, 1211, 1216, "7 . 7", "", "<http://ctro/data#Outcome_30827> <http://ctro/data#hasBaselineValue> \"7 . 7\"."
151, SdDevBL, 1223, 1228, "0 . 1", "", "<http://ctro/data#Outcome_30827> <http://ctro/data#hasSdDevBL> \"0 . 1\"."
101, Percentage, 1229, 1230, "%", "", "<http://ctro/data#Endpoint_30702> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
110, TimePoint, 1248, 1255, "week 12", "", "<http://ctro/data#Outcome_30827> <http://ctro/data#hasTimePoint> \"week 12\". <http://ctro/data#Outcome_30854> <http://ctro/data#hasTimePoint> \"week 12\"."
154, Reduction, 1268, 1273, "0 . 6", "", "<http://ctro/data#Outcome_30827> <http://ctro/data#hasChangeValue> \"0 . 6\"."
155, SdDevChangeValue, 1280, 1285, "0 . 1", "", "<http://ctro/data#Outcome_30827> <http://ctro/data#hasSdDevChangeValue> \"0 . 1\"."
102, Percentage, 1286, 1287, "%", "", 
43, HbA1c, 1300, 1305, "HbA1c", "", 
93000, ObservedResult, 1306, 1336, "did not change from a baseline", "", "<http://ctro/data#Outcome_30854> <http://ctro/data#hasObservedResult> \"did not change from a baseline\"."
44, BaseLineValue, 1340, 1345, "7 . 9", "", "<http://ctro/data#Outcome_30854> <http://ctro/data#hasBaselineValue> \"7 . 9\"."
159, SdDevBL, 1352, 1357, "0 . 1", "", "<http://ctro/data#Outcome_30854> <http://ctro/data#hasSdDevBL> \"0 . 1\"."
103, Percentage, 1358, 1359, "%", "", 
46, Placebo, 1378, 1385, "placebo", "", 
47, DiffGroupAbsValue, 1431, 1438, "- 0 . 7", "", "<http://ctro/data#DiffBetweenGroups_41712> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 7\"."
162, SdDevDiff, 1445, 1450, "0 . 1", "", "<http://ctro/data#DiffBetweenGroups_41712> <http://ctro/data#hasStandardDevDiff> \"0 . 1\"."
104, Percentage, 1451, 1452, "%", "", 
49, PvalueDiff, 1455, 1467, "P < 0 . 0001", "", "<http://ctro/data#DiffBetweenGroups_41712> <http://ctro/data#hasPvalueDiff> \"P < 0 . 0001\"."
114, Mean, 1472, 1476, "Mean", "", 
219, PostprandialBloodGlucose, 1477, 1493, "prandial glucose", "", "<http://ctro/data#Endpoint_30707> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PostprandialBloodGlucose>."
50, FastingPlasmaGlucose, 1498, 1501, "FPG", "", "<http://ctro/data#Endpoint_30712> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
38507, Vildagliptin, 1551, 1557, "LAF237", "", 
53, Placebo, 1565, 1572, "placebo", "", 
168, Reduction, 1576, 1581, "2 . 2", "", "<http://ctro/data#Outcome_13070> <http://ctro/data#hasChangeValue> \"2 . 2\"."
170, SdDevChangeValue, 1588, 1593, "0 . 4", "", "<http://ctro/data#Outcome_13070> <http://ctro/data#hasSdDevChangeValue> \"0 . 4\"."
56, Millimoles_per_litre, 1594, 1602, "mmol / l", "", "<http://ctro/data#Endpoint_30707> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Millimoles_per_litre>."
38508, PValueChangeValue, 1605, 1617, "P < 0 . 0001", "", "<http://ctro/data#Outcome_13070> <http://ctro/data#hasPValueChangeValue> \"P < 0 . 0001\"."
172, Reduction, 1624, 1629, "1 . 2", "", "<http://ctro/data#Outcome_30773> <http://ctro/data#hasChangeValue> \"1 . 2\"."
174, SdDevChangeValue, 1636, 1641, "0 . 4", "", "<http://ctro/data#Outcome_30773> <http://ctro/data#hasSdDevChangeValue> \"0 . 4\"."
60, Millimoles_per_litre, 1642, 1650, "mmol / l", "", 
38509, PValueChangeValue, 1653, 1665, "P = 0 . 0057", "", "<http://ctro/data#Outcome_30773> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 0057\"."
93001, Insulin, 1689, 1703, "plasma insulin", "", 
62, ObservedResult, 1704, 1728, "levels were not affected", "", "<http://ctro/data#Outcome_30800> <http://ctro/data#hasObservedResult> \"levels were not affected\"."
113, TimePoint, 1734, 1760, "end point of the extension", "", 
115, Mean, 1808, 1812, "mean", "", 
179, EndPointDescription, 1813, 1829, "prandial glucose", "", 
93002, Insulin, 1832, 1839, "insulin", "", 
65, FastingPlasmaGlucose, 1846, 1849, "FPG", "", 
74, DiffGroupAbsValue, 1855, 1862, "- 2 . 4", "", 
184, SdDevDiff, 1869, 1874, "0 . 6", "", 
76, Millimoles_per_litre, 1875, 1883, "mmol / l", "", 
77, PvalueDiff, 1886, 1898, "P = 0 . 0001", "", 
78, DiffGroupAbsValue, 1903, 1905, "40", "", 
192, SdDevDiff, 1912, 1914, "16", "", 
80, Picomole_per_liter, 1915, 1923, "pmol / l", "", 
81, PvalueDiff, 1926, 1938, "P = 0 . 0153", "", 
82, DiffGroupAbsValue, 1947, 1954, "- 1 . 1", "", 
185, SdDevDiff, 1961, 1966, "0 . 5", "", 
84, Millimoles_per_litre, 1967, 1975, "mmol / l", "", 
85, PvalueDiff, 1978, 1990, "P = 0 . 0312", "", 
93003, ObservedResult, 2010, 2054, "HbA1c did not change from week 12 to week 52", "", "<http://ctro/data#Outcome_30827> <http://ctro/data#hasObservedResult> \"HbA1c did not change from week 12 to week 52\"."
86, HbA1c, 2010, 2015, "HbA1c", "", 
93, TimePoint, 2036, 2043, "week 12", "", 
92, TimePoint, 2047, 2054, "week 52", "", 
38505, Vildagliptin, 2058, 2064, "LAF237", "", 
93005, NumberPatientsArm, 2090, 2092, "42", "", 
93004, ObservedResult, 2099, 2138, "increased in participants given placebo", "", 
94, Placebo, 2131, 2138, "placebo", "", 
93006, NumberPatientsArm, 2145, 2147, "29", "", 
203, TimePoint, 2203, 2209, "1 year", "", 
97, DiffGroupAbsValue, 2214, 2221, "- 1 . 1", "", 
205, SdDevDiff, 2228, 2233, "0 . 2", "", 
99, Percentage, 2234, 2235, "%", "", 
100, PvalueDiff, 2238, 2250, "P < 0 . 0001", "", 
218, ConclusionComment, 2269, 2425, "Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes .", "", "<http://ctro/data#ClinicalTrial_30677> <http://ctro/data#hasConclusionComment> \"Data from this study demonstrate that LAF237 effectively prevents deterioration of glycemic control when added to metformin monotherapy in type 2 diabetes .\"."
38504, Vildagliptin, 2307, 2313, "LAF237", "", 
107, Metformin, 2383, 2392, "metformin", "", 
108, Type2Diabetes, 2408, 2423, "type 2 diabetes", "", 
6, PMID, 2476, 2484, "15562200", "", "<http://ctro/data#Publication_30666> <http://ctro/data#hasPMID> \"15562200\"."
